Piper Jaffray analyst Christopher Raymond is "incrementally positive" on Alexion shares following the company's "strong across-the-board" Q2 results. The stock, however, remains range-bound on "unfounded" concerns over the trajectory of Soliris/Ultomiris and the company's ability to diversify away from the franchise, Raymond tells investors in a research note. The analyst continued to think patient investors will be rewarded and he reiterates an Overweight rating on Alexion with a $180 price target. He continues to like the setup at current share levels.